http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 10 Aug 2026 16:18:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Agomab+Therapeutics+NV++++For%3A+Aug+10/26898209.html si-local-file:///var/storage/secattach/20260810/26898209.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Agomab+Therapeutics+NV++++For%3A+Aug+10/26898209.html Mon, 10 Aug 2026 16:18:00 -0400 AGMB O.31844339 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Agomab+Therapeutics+NV++++For%3A+Aug+10/26898209.html si-local-file:///var/storage/secattach/20260810/26898209.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Agomab+Therapeutics+NV++++For%3A+Aug+10/26898209.html Mon, 10 Aug 2026 16:18:00 -0400 AGMB O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897857.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a press release from the Antwerp, Belgium-based company. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026.</p> <p>Garcia currently serves as President, Chief Executive Officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, Aspreva Pharmaceuticals, Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as Chief Medical Officer of CRISPR Therapeutics (Nasdaq: CRSP). Before that role, he http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897857.html Mon, 10 Aug 2026 16:08:12 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897857.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a press release from the Antwerp, Belgium-based company. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026.</p> <p>Garcia currently serves as President, Chief Executive Officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, Aspreva Pharmaceuticals, Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as Chief Medical Officer of CRISPR Therapeutics (Nasdaq: CRSP). Before that role, he http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897857.html Mon, 10 Aug 2026 16:08:12 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897857.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a press release from the Antwerp, Belgium-based company. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026.</p> <p>Garcia currently serves as President, Chief Executive Officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, Aspreva Pharmaceuticals, Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as Chief Medical Officer of CRISPR Therapeutics (Nasdaq: CRSP). Before that role, he http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897857.html Mon, 10 Aug 2026 16:08:12 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html <p>Agomab Therapeutics NV (Nasdaq: AGMB) has proposed appointing Marino Garcia and Naimish Patel, M.D. as non-executive members of its board of directors, according to a company statement. The appointments are subject to shareholder approval at a Special General Meeting scheduled for September 11, 2026, in Antwerp, Belgium.</p> <p>Garcia currently serves as president, chief executive officer, and board member of Dianthus Therapeutics (Nasdaq: DNTH). He has previously held senior roles at Zealand Pharma, Synergy Pharmaceuticals, Aptalis Pharma, and Aspreva Pharmaceuticals, as well as commercial and strategic positions at Merck, Pfizer, and Eli Lilly.</p> <p>Dr. Patel currently serves as chief medical officer of CRISPR http://www.streetinsider.com/Board+Changes/Agomab+proposes+two+new+board+members+ahead+of+shareholder+vote/26897832.html Mon, 10 Aug 2026 16:07:33 -0400 A.12013808 A.35954321 A.36327400 AGMB CRSP DNTH O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html Mon, 10 Aug 2026 16:07:15 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html Mon, 10 Aug 2026 16:07:15 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html Mon, 10 Aug 2026 16:07:15 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Globe+Newswire/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Globe+Newswire/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html Mon, 10 Aug 2026 16:07:15 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Globe+Newswire/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Globe+Newswire/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html Mon, 10 Aug 2026 16:07:15 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Globe+Newswire/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company's Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Globe+Newswire/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors+/26897851.html Mon, 10 Aug 2026 16:07:15 -0400 AGMB CRSP DNTH http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors/26897825.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company&apos;s Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors/26897825.html Mon, 10 Aug 2026 16:07:00 -0400 A.12013808 A.35954321 A.36327400 AGMB O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors/26897825.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company&apos;s Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors/26897825.html Mon, 10 Aug 2026 16:07:00 -0400 A.12013808 A.35954321 A.36327400 AGMB O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors/26897825.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company&apos;s Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors/26897825.html Mon, 10 Aug 2026 16:07:00 -0400 A.12013808 A.35954321 A.36327400 AGMB O.16534670 O.20737027 O.22651798 O.31844339 http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors/26897825.html <p align="justify"><b>Antwerp, Belgium, August 10, 2026</b> – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of <b>Marino Garcia</b> and <b>Naimish Patel, M.D.</b> as non-executive members of the Board of Directors. The appointments will be submitted for shareholder approval at the Company&apos;s Special General Meeting to be held on September 11, 2026.</p> <p align="justify">“We are delighted to nominate Marino and Naimish to join Agomab’s Board of Directors,” said <b>David Epstein, Chairman of the Board of Agomab</b>. “Marino brings extensive experience http://www.streetinsider.com/Press+Releases/Agomab+Announces+Proposed+Appointments+of+Marino+Garcia+and+Dr.+Naimish+Patel+to+Board+of+Directors/26897825.html Mon, 10 Aug 2026 16:07:00 -0400 A.12013808 A.35954321 A.36327400 AGMB O.16534670 O.20737027 O.22651798 O.31844339